Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2.

The global spread of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has provoked an urgent need for prophylactic measures. Several innovative vaccine platforms have been introduced and billions of vaccine doses have been administered worldwide. To enable the creation of safer and more effective vaccines, additional platforms are under development. These include the use of nanoparticle (NP) and virus-like particle (VLP) technology. NP vaccines utilize self-assembling scaffold structures designed to load the entire spike protein or receptor-binding domain of SARS-CoV-2 in a trimeric configuration. In contrast, VLP vaccines are genetically modified recombinant viruses that are considered safe, as they are generally replication-defective. Furthermore, VLPs have indigenous immunogenic potential due to their microbial origin. Importantly, NP and VLP vaccines have shown stronger immunogenicity with greater protection by mimicking the physicochemical characteristics of SARS-CoV-2. The study of NP- and VLP-based coronavirus vaccines will help ensure the development of rapid-response technology against SARS-CoV-2 variants and future coronavirus pandemics. © 2022. The Microbiological Society of Korea.

Citation

Chulwoo Kim, Jae-Deog Kim, Sang-Uk Seo. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. Journal of microbiology (Seoul, Korea). 2022 Mar;60(3):335-346

Mesh Tags

Substances

PMID: 35089583

search → result